Pipeline

Pipeline Overview

BerGenBio is focused on developing a pipeline of transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory illnesses

Happy couple
Candidate
Preclinical
Phase 1
Phase 2

Oncology

Bemcentinib
Targeted Indication1L STK11m NSCLC

Targeted Indication

1L STK11m NSCLC
Phase 1b/2a
Targeted Indication2L NSCLC

Targeted Indication

2L NSCLC
Phase 2
Targeted IndicationAML/MDS

Targeted Indication

AML/MDS
Phase 2
Mipasetamab
uzoptirine
Targeted IndicationSolid Tumors

Targeted Indication

Solid Tumors
Phase 1

Severe
respiratory
infections

Bemcentinib
Targeted IndicationSevere respiratory infections in hospitalized patients
Severe respiratory infections in hospitalized patients
Phase 2
Targeted IndicationARDS
ARDS
Preclinical

Fibrosis

Tilvestamab
Targeted IndicationFibrotic Diseases

Targeted Indication

Fibrotic Diseases
Phase 1

Note : Bemcentinib is also being studied in Investigator Led Trials in glioblastoma, 2L lung cancer, melanoma, pancreatic cancer, and mesothelioma.